<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04797182</url>
  </required_header>
  <id_info>
    <org_study_id>B2021-034</org_study_id>
    <nct_id>NCT04797182</nct_id>
  </id_info>
  <brief_title>Avatrombopag for the Primary Prevention of Thrombocytopenia Induced by Cytarabine-based Chemotherapy in Patients With Lymphoma</brief_title>
  <official_title>Avatrombopag for the Primary Prevention of Thrombocytopenia Induced by Cytarabine-based Chemotherapy in Patients With Lymphoma: An Open, Single-center, Phase II Randomized Controlled Clinical Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sun Yat-sen University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase 2 trial studies the efficacy and safety of Avatrombopag for the primary prevention&#xD;
      of thrombocytopenia induced by cytarabine-based chemotherapy in patients with lymphoma&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 2021</start_date>
  <completion_date type="Anticipated">July 2023</completion_date>
  <primary_completion_date type="Anticipated">April 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The incidence of grades III and IV thrombocytopenia</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The durations of any grade thrombocytopenia and grades II, III and IV thrombocytopenia</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">46</enrollment>
  <condition>Thrombocytopenia</condition>
  <condition>Cytarabine Causing Adverse Effects in Therapeutic Use</condition>
  <condition>Lymphoma</condition>
  <arm_group>
    <arm_group_label>blank control</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>No intervention aiming at preventing thrombocytopenia will be taken after first cycle. Avatrombopag as salvage treatment will be administered to patients suffering from thrombocytopenia with nadir platelet count &lt; 50 × 109/L at a dose of 60mg/day until there is drug-withdrawal indication.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>primary prevention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>As the primary prevention of thrombocytopenia induced by cytarabine-based chemotherapy, Avatrombopag will be administered at a dose of 60mg/day on days -3~-1 and 3~9, for a total of 10 doses. On the condition that patients have platelet counts &lt;50 × 10 9 /L before next cycle, Avatrombopag will be administered at a dose of 60mg/day until there is drug-withdrawal indications. Platelet transfusions were administered to patients when the platelet count was less than 10×109 /L.&#xD;
Drug-withdrawal indications:&#xD;
PLT ≥ 100×109/L during salvage treatment or platelet count increases by 50×109/L, comparing with baseline level.&#xD;
When platelet count is higher than 400×109/L during this study, researchers determine whether avatrombopag is discontinued</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>avatrombopag</intervention_name>
    <description>avatrombopag,60 mg/d,po</description>
    <arm_group_label>blank control</arm_group_label>
    <arm_group_label>primary prevention</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically confirmed lymphoma;&#xD;
&#xD;
          -  Patients are scheduled to receive cytarabine-based chemotherapy including Ara-C at&#xD;
             dose of 4g/m2.&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) of 0-1;&#xD;
&#xD;
          -  Proper functioning of the major organs: 1) The absolute value of neutrophils&#xD;
             (&gt;1.5×10^9/L); platelet count (&gt; 100×10^9/L); Hemoglobin (&gt; 90 g/L); 2) Serum total&#xD;
             bilirubin &lt; 1.5 times ULN; Aspartate Aminotransferase (AST), Alanine Aminotransferase&#xD;
             (ALT) &lt; 3 times ULN;3) Serum creatinine &lt;1.5 times Upper Limit Normal (ULN) ; 4)&#xD;
             Coagulation function: International Normalized Ratio (INR), Prothrombin Time (PT)&lt; 1.5&#xD;
             times ULN&#xD;
&#xD;
          -  Able to use oral drugs&#xD;
&#xD;
          -  Patients volunteer to sign an informed consent&#xD;
&#xD;
          -  Life expectancy &gt; 3 months;&#xD;
&#xD;
          -  Contraceptives are used&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Thrombocytopenia unrelated to chemotherapy during six months before screening,&#xD;
             including but not limited to hypersplenism, infection and hemorrhage.&#xD;
&#xD;
          -  In addtion to CIT caused by lymphoma and chemotherapy,patients also suffer from other&#xD;
             blood diseases including ALL, AML, myeloid neoplasms, MDS, myeloproliferative&#xD;
             disorders, MM;&#xD;
&#xD;
          -  A thrombosis of a coronary artery or vein developed during three months before&#xD;
             screening;&#xD;
&#xD;
          -  Haemorrhage with severe clinical symptoms, such as gastrointestinal and cerebral&#xD;
             hemorrhage;&#xD;
&#xD;
          -  Platelet transfusion during two days before randomization;&#xD;
&#xD;
          -  Allergic to avatrombopag;&#xD;
&#xD;
          -  Participation in any other research about novel agents or devices;&#xD;
&#xD;
          -  Pregnant or breastfeeding women;&#xD;
&#xD;
          -  Researchers consider it unsuitable for patients to participate in this study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Qingqing Cai, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sun Yat-sen University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Qingqing Cai, MD</last_name>
    <phone>0086-20-87342823</phone>
    <email>caiqq@sysucc.org.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Cai</last_name>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Sun Yat-sen University Cancer Center</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510060</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Qingqing Cai, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 11, 2021</study_first_submitted>
  <study_first_submitted_qc>March 11, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 15, 2021</study_first_posted>
  <last_update_submitted>March 11, 2021</last_update_submitted>
  <last_update_submitted_qc>March 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sun Yat-sen University</investigator_affiliation>
    <investigator_full_name>Qingqing Cai</investigator_full_name>
    <investigator_title>Chief physician</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Thrombocytopenia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

